Dr. Okarma to tell more about progress at ASH conference Dec. 9-12th
Here are the abstracts/info I pulled from the conference program.
.  GRN163L, a Potent and Specific Inhibitor of Telomerase: Integrated Pharmacokinetic, Pharmacodynamic, and Safety Data Guides Design of Practical Treatment Regimens for Targeting Inhibitory Levels in Patients. Session Type: Poster Session, Board #773-II Authors: Robert J. Tressler, Allison C. Chin, Eric J. Feldman, Kanti R. Rai, Doug Kornbrust, Calvin B. Harley, Melissa A. Kelly Behrs, Laurence Elias Date/Time: Sunday, December 10, 2006 - 9:00 AM Session Info: Poster Session: Molecular Pharmacology, Drug Resistance II (9:00 AM-8:00 PM)
4.  Cancer Stem Cell Targeting in Multiple Myeloma by GRN163L, a Novel and Potent Telomerase Inhibitor. Session Type: Poster Session, Board #718-II Authors: William Matsui, Qiuju Wang, Milada Vala, James P. Barber, Alan Meeker, Robert Tressler, Calvin Harley, Carol A. Huff, B. Douglas Smith, Richard J. Jones Date/Time: Sunday, December 10, 2006 - 9:00 AM Session Info: Poster Session: Malignant Stem and Progenitor Cells (9:00 AM-8:00 PM)